Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
Of these patients, 1,284 met the inclusion criteria, 128 actively used a GLP-1RA, and 1,156 were not using a GLP-1RA
levels below 400 pg/mL may affect hair despite being normal range. Complete Blood Count (CBC) screens for anemia, which dramatically impacts hair growth
To view or add a comment, sign in 88% of self-funded employers face stop-loss claims annually, highlighting the prevalence of high-cost health events Learn about top health conditions, injectable drugs and strategies to improve employee wellbeing while controlling costs
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity